Validity and Reliability of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity Questionnaire
Launched by ISTANBUL UNIVERSITY - CERRAHPASA · Jun 11, 2024
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new questionnaire called the Inflammatory Arthritis Facilitators and Barriers to Physical Activity (IFAB) Questionnaire. The goal of this questionnaire is to understand what helps or stops children with certain rheumatic diseases, like juvenile idiopathic arthritis and juvenile dermatomyositis, from being physically active. Being active is very important for these children to help manage their conditions and reduce health risks. The researchers want to make sure that this questionnaire is both valid (measuring what it’s supposed to measure) and reliable (giving consistent results over time).
To participate in this study, children aged 12 to 18 who have been diagnosed with juvenile idiopathic arthritis, juvenile dermatomyositis, or juvenile fibromyalgia syndrome by a pediatric rheumatologist can volunteer. They must be living in Turkey and not have any significant vision or hearing problems that would prevent them from understanding the questionnaire. The trial is not yet recruiting participants, but once it starts, those who join will help contribute to important research that could lead to better support for children facing these challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Volunteer
- • 12-18 ages
- • Diagnosed with juvenile idiopathic arthritis, juvenile dermatomyositis and juvenile fibromyalgia syndrome by a pediatric rheumatologist
- • Residing in Turkey
- Exclusion Criteria:
- • Having a vision or hearing problem
- • Difficulty adhering to the treatment program
About Istanbul University Cerrahpasa
Istanbul University - Cerrahpasa is a prestigious academic institution renowned for its commitment to advancing medical research and education. With a focus on innovative clinical trials, the university harnesses cutting-edge methodologies to address pressing health challenges. Its collaborative environment fosters interdisciplinary research, enabling the development of effective therapeutic strategies and enhancing patient care. The institution's dedication to ethical standards and patient safety underscores its reputation as a leader in clinical research within the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Trial Officials
Nilay Arman, Asst. Prof.
Principal Investigator
Istanbul University - Cerrahpasa
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported